SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
8,81 USD
arrow_upward
+1,50%(+0,13) 1 zi
13 oct., 16:00:00 GMT-4 · USD
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru SGIOY...
Deschide
8,66 USD
Mare
8,85 USD
Mic
8,66 USD
Capitalizarea bursieră
2,50 tril.
Volum mediu
169,23 K
Volum
118,89 K
Prețul ridicat pe 52 de săptămâni
12,00 USD
Prețul redus pe 52 de săptămâni
7,65 USD
Beta
0,07
Acțiuni aflate în circulație
1,78 mld.
Nr. de angajați
6 K
Deschide
8,66 USD
Mare
8,85 USD
Mic
8,66 USD
Capitalizarea bursieră
2,50 tril.
Volum mediu
169,23 K
Volum
118,89 K
Prețul ridicat pe 52 de săptămâni
12,00 USD
Prețul redus pe 52 de săptămâni
7,65 USD
Beta
0,07
Acțiuni aflate în circulație
1,78 mld.
Nr. de angajați
6 K
Subiecte de știri
Din surse web și de la parteneri de știri
Vietnam.vn
·
acum 22 de ore
Indicele compozit Nasdaq a scăzut înainte de sezonul de raportare a rezultatelor financiare.
Vietnam.vn
·
acum 22 de ore
Acțiuni americane: Indicele compozit Nasdaq scade înainte de sezonul de raportare a rezultatelor financiare.
The National Law Review
·
acum 6 minute
Kaplan Fox Encourages The Ensign Group, Inc. (NASDAQ: ENSG) Inves
Simply Wall Street
·
acum 4 minute
How Investors May Respond To Semtech (SMTC) Securing AI Chip Capacity
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Despre Shionogi 2 ADR Representing 1 Ord Shs